57576-44-0 (阿克拉霉素,Aclarubicin)

阿克拉霉素;阿克拉霉素A;阿柔比星;安乐霉素;阿柔比星,阿克拉霉素A;(S)-6-[(3,5-二甲基-1H-吡唑-4-基)甲基]-5-[(4-羟基异唑烷-2-基)羰基]-1-异丁基-3-甲基噻吩并[2,3-D]嘧啶-2,4(1H,3H)-二酮;盐酸阿柔比星;

Aclarubicin;Methyl (1R,2R,4S)-4-[(2R,5S,6S)-4-dimethylamino-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate;ACLACINOMYCIN A,STREPTOMYCES GALILAEUS;Aclacin;aclacur;Aclaplastin;ACLARUBLCIN;ACM;Aelacinon;Jaclacin;ma144-a1;Aclacinomycin A;CHEBI:77980;57576-44-0;Aclarubicine [INN-French];UNII-74KXF8I502;ACLARUBICIN [JAN];KBio2_006083;ACLARUBICIN [WHO-DD];Spectrum_000467;Aclarubicinum;Spectrum5_001041;DTXSID1022554;KBio2_000947;USZYSDMBJDPRIF-SVEJIMAYSA-N;aclarubicina;Spectrum4_000768;MA 144-A1;D02756;Aclarubicinum [INN-Latin];DB11617;Aclarubicin [USAN:INN:BAN];ACLARUBICIN [USAN];ACLARUBICIN [INN];SCHEMBL4532;CS-0020062;1-Naphthacenecarboxylic acid,2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-a-L-lyxo-hexopyranosyl]-3-(dimethylamino)-a-L-lyxo-hexopyranosyl]oxy]-, methyl ester, [1R-(1a,2b,4b)]-;SPBio_001967;Q4674302;CHEMBL502620;ACLACINOMYCIN A [MI];Aclarubicins;KBioGR_001156;CHEBI:74619;Aclarunbicin;HMS2089B13;BDBM50368351;KBio2_003515;Spectrum2_001934;HY-N2306;KBioSS_000947;ACLARUBICIN [MART.];AW8655;MFCD00866250;NS00003246;1-Naphthacenecarboxylic acid, 2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)oxy)-, methyl ester, (1R-(1alpha,2beta,4beta))-;Methyl (1R,2R,4S)-2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R,6S)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)oxy)-1-naphthacenecarboxylate;Aclarubicin (USAN/INN);Antibiotic MA 144A;AB00052311-02;EINECS 260-824-3;74KXF8I502;1-Naphthacenecarboxylic acid,(2-ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-((2,3,6-trideoxy-4-O-(2,6-dideoxy-4-O-((2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl)-3-(dimethylamino)-alpha-L-Lyxo-hexopyranosyl)oxy)-, methyl ester, (1R-(1alpha,2beta,4beta))-;methyl (1R,2R,4S)-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-4-{[2,3,6-trideoxy-4-O-{2,6-dideoxy-4-O-[(2R,6S)-6-methyl-5-oxotetrahydro-2H-pyran-2-yl]-alpha-L-lyxo-hexopyranosyl}-3-(dimethylamino)-alpha-L-lyxo-hexopyranosyl]oxy}-1,2,3,4,6,11-hexahydrotetracene-1-carboxylate;Antibiotic MA 144A1;methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxooxan-2-yl]oxyoxan-2-yl]oxy-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate;NSC-208734;Aclarubicino [INN-Spanish];methyl (1R,2R,4S)-4-[(2R,4S,5S,6S)-4-(dimethylamino)-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[(2R,6S)-6-methyl-5-oxo-tetrahydropyran-2-yl]oxy-tetrahydropyran-2-yl]oxy-6-methyl-tetrahydropyran-2-yl]oxy-2-ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1-carboxylate;Aclarubicino;CCRIS 2262;2-Ethyl-1,2,3,4,6,11-hexahydro-2,5,7-trihydroxy-6,11-dioxo-4-[[2,3,6-trideoxy-4-O-[2,6-dideoxy-4-O-[(2R-trans)-tetrahydro-6-methyl-5-oxo-2H-pyran-2-yl]-.alpha.-L-lyxo-hexopyranosyl]-3-(dimethylamino)-.alpha.-L-lyxo-hexopyranosyl]-oxy]-1-naphthacenecarboxalic acid methyl ester;Aclacinon;ACLACINOMYCIN A1;Aclarubicine;C18638;CCG-39864;Antibiotic 3082A;NSC 208734;Aclacinomycin;Aclucinomycin A;Antibiotic 77-3082A;Antibiotic MA144-A1;

MFCD00866250

USZYSDMBJDPRIF-SVEJIMAYSA-N

InChI=1S/C42H53NO15/c1-8-42(51)17-28(33-22(35(42)41(50)52-7)14-23-34(38(33)49)37(48)32-21(36(23)47)10-9-11-26(32)45)56-30-15-24(43(5)6)39(19(3)54-30)58-31-16-27(46)40(20(4)55-31)57-29-13-12-25(44)18(2)53-29/h9-11,14,18-20,24,27-31,35,39-40,45-46,49,51H,8,12-13,15-17H2,1-7H3/t18-,19-,20-,24-,27-,28-,29-,30-,31-,35-,39+,40+,42+/m0/s1

O([C@H]1C[C@@H]([C@@H]([C@H](C)O1)O[C@H]1C[C@@H]([C@@H]([C@H](C)O1)O[C@H]1CCC([C@H](C)O1)=O)O)N(C)C)[C@@H]1C2=C(C3C(C4C(=CC=CC=4C(C=3C=C2[C@@H](C(=O)OC)[C@@](CC)(C1)O)=O)O)=O)O

260-824-3

发酵制取,产生菌为Streptomyces galilacus。先准备含有下列物质的水溶液:1%的土豆粉,1%的葡萄糖,1.5%的Prorich,0.1%的KH2PO4,0.1%的KH2PO4,0.1%的MgSO47H2O,0.3%的NaCl,0.15%的复合矿物质和0.05%的硅酮(KM75),该水溶液的Ph值为7.0。复合矿物质的成分为:2.8g的CuSO45H2O,0.4g的FeSO47H2O,3.2g的MnCl24H2O和0.8g的ZnSO47H2O溶于500ml水中。 100ml上述水溶液在500ml的接有Streptomyces galilaeus MA 144-M1菌种的震荡瓶中,于120℃消毒15min。在往复振荡器中,于28℃进行48h的培养,得到种子液。上述10L的消毒液放入20L的不锈钢发酵罐中,用200ml的种子液接种。在搅拌(240r/min)和充气(5L/min)及28℃下,发酵32h。调至Ph=4.5,和硅藻土吸附剂混合,过滤。该发酵液的滤液和滤饼分别处理。滤饼悬浮于丙酮(3L/kg湿滤饼),搅拌2h后过滤,滤饼再用丙酮提取1次。如此得到的提取液减压浓缩至1/10体积。发酵液的滤液调至Ph=6.8,用1/3体积的乙酸乙酯提取2次,提取液减压浓缩至1/10体积。得到的20g油状物和20g硅酸混合,用硅酸柱进行层析,先以1:1的苯一丙酮洗脱,该洗脱液废弃。然后以1:3:0和1:3:0.3的苯-丙酮-甲醇洗脱,收集,减压浓缩至干。剩下的11.5g粗品溶于小量乙酸乙酯,再如上进行硅酸柱层析,开始的1:1和2:1的苯-丙酮洗脱液废弃。以1:3和1:5的苯-丙酮将阿克拉霉素B洗脱,然后以1:5:0.5和1:5:1的苯-丙酮-甲醇将阿柔比星洗脱。洗脱液用无水硫酸钠干燥,减压浓缩至干,得到4.8g阿柔比星(阿克拉霉素A)和3.5g阿克拉霉素B的粗品。 2.0g阿柔比星粗品溶于小量氯仿,用30g硅胶进行柱层析,先用氯仿和含1.5%甲醇的氯仿溶液将杂质洗脱后,再用含2%甲醇的氯仿溶液将阿柔比星洗脱。洗脱液减压浓缩至干,得到53mg黄色粉末的阿柔比星,熔点129--135℃。